- Home
- DAWN vs LPTH Comparison
DAWN vs LPTH Comparison
Compare DAWN & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- LPTH
- Stock Information
- Founded
- DAWN 2018
- LPTH 1985
- Country
- DAWN United States
- LPTH United States
- Employees
- DAWN N/A
- LPTH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- LPTH Semiconductors
- Sector
- DAWN Health Care
- LPTH Technology
- Exchange
- DAWN Nasdaq
- LPTH Nasdaq
- Market Cap
- DAWN 1.3B
- LPTH N/A
- IPO Year
- DAWN 2021
- LPTH 1996
- Fundamental
- Price
- DAWN $12.79
- LPTH $2.69
- Analyst Decision
- DAWN Strong Buy
- LPTH Strong Buy
- Analyst Count
- DAWN 7
- LPTH 2
- Target Price
- DAWN $36.17
- LPTH $3.00
- AVG Volume (30 Days)
- DAWN 937.9K
- LPTH 356.6K
- Earning Date
- DAWN 10-30-2024
- LPTH 02-06-2025
- Dividend Yield
- DAWN N/A
- LPTH N/A
- EPS Growth
- DAWN N/A
- LPTH N/A
- EPS
- DAWN N/A
- LPTH N/A
- Revenue
- DAWN $101,953,000.00
- LPTH $32,049,325.00
- Revenue This Year
- DAWN N/A
- LPTH $12.63
- Revenue Next Year
- DAWN $36.10
- LPTH $16.80
- P/E Ratio
- DAWN N/A
- LPTH N/A
- Revenue Growth
- DAWN N/A
- LPTH N/A
- 52 Week Low
- DAWN $11.94
- LPTH $1.04
- 52 Week High
- DAWN $18.07
- LPTH $2.86
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- LPTH 84.03
- Support Level
- DAWN $12.26
- LPTH $2.36
- Resistance Level
- DAWN $12.81
- LPTH $2.86
- Average True Range (ATR)
- DAWN 0.52
- LPTH 0.23
- MACD
- DAWN -0.05
- LPTH 0.09
- Stochastic Oscillator
- DAWN 28.94
- LPTH 84.68
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.